Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease

被引：0
作者：
Vera S. Kerstens
Patrik Fazio
Mathias Sundgren
Granville J. Matheson
Erika Franzén
Christer Halldin
Simon Cervenka
Per Svenningsson
Andrea Varrone
机构：
[1] Karolinska University Hospital,Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm
[2] Karolinska Institutet,Department of Clinical Neuroscience, Division of Neuro
[3] Karolinska University Hospital,Neurology Department
[4] Karolinska Institutet,Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy
[5] Karolinska University Hospital,Function Area Occupational Therapy & Physiotherapy, Allied Health Professionals Function
来源：
EJNMMI Research | / 10卷
关键词：
Reliability; Test-retest; [; F]FE-PE2I; Dopamine transporter; Parkinson’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 129 条
[1]  
Schou M(2009)Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter Bioorg Med Chem Lett 19 4843-4845
[2]  
Steiger C(2009)In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand Synapse. 63 871-880
[3]  
Varrone A(2011)Simplified quantification and whole-body distribution of 18F-FE-PE2I in nonhuman primates: prediction for human studies J Nucl Med 52 132-139
[4]  
Guilloteau D(2012)Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I Nucl Med Biol 39 295-303
[5]  
Halldin C(2012)Quantitative analysis of 18F-(E)-N-(3-iodoprop-2-enyl)-2-carbofluoroethoxy-3-(4′-methyl-phenyl) nortropane binding to the dopamine transporter in Parkinson disease J Nucl Med 53 1065-1073
[6]  
Varrone A(2015)Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in healthy controls and Parkinson’s disease patients J Nucl Med 56 714-720
[7]  
Steiger C(2016)Whole-body biodistribution and dosimetry of the dopamine transporter radioligand 18fF-Fe-PE2I in human subjects J Nucl Med 57 1529-1534
[8]  
Schou M(2018)Nigrostriatal dopamine transporter availability in early Parkinson’s disease J Nucl Med 59 1275-1280
[9]  
Varrone A(2018)Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease Mov Disord 33 592-599
[10]  
Toth M(2013)Validation of nigrostriatal positron emission tomography measures: critical limits Brain 136 2419-2431
12345678910